<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page_3_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page_3_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>jennifer</o:LastAuthor>
  <o:Revision>21</o:Revision>
  <o:TotalTime>46</o:TotalTime>
  <o:Created>2003-09-02T14:00:00Z</o:Created>
  <o:LastSaved>2003-09-03T15:19:00Z</o:LastSaved>
  <o:Pages>3</o:Pages>
  <o:Words>1305</o:Words>
  <o:Characters>7441</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>62</o:Lines>
  <o:Paragraphs>14</o:Paragraphs>
  <o:CharactersWithSpaces>9138</o:CharactersWithSpaces>
  <o:Version>9.4402</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>150</w:Zoom>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:28.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Times New Roman";
	color:navy;
	mso-font-kerning:0pt;}
h2
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:Arial;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1029"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/potm/archive.html"
title="To Protein Archive"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1027" type="#_x0000_t75" style='width:113.25pt;
 height:36.75pt'>
 <v:imagedata src="./Page_3_files/image001.jpg" o:title="InterPro_logo"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=151 height=49
src="./Page_3_files/image001.jpg" v:shapes="_x0000_i1027"><![endif]></a></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1>Oestrogen Receptors</h1>

<h1 align=left style='text-align:left'><span style='font-size:16.0pt;
mso-bidi-font-size:12.0pt;font-family:Arial'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></h1>

<h1 align=left style='text-align:left'><span style='font-size:16.0pt;
mso-bidi-font-size:12.0pt;font-family:Arial'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></h1>

<h1 align=left style='text-align:left'><span style='font-size:16.0pt;
mso-bidi-font-size:12.0pt;font-family:Arial'>The physiological roles of the
oestrogen receptors<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>The ERs
control a variety of different physiological processes, and they have been implicated
in numerous diseases.<span style="mso-spacerun: yes">  </span>Below are some of
the major areas of oestrogen involvement.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1 align=left style='text-align:left'><i><span style='font-size:14.0pt;
mso-bidi-font-size:12.0pt;font-family:Arial'>Female and male reproduction<o:p></o:p></span></i></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>In females,
the distribution and roles of ER<span style='font-family:Symbol'>a</span> and
ER<span style='font-family:Symbol'>b</span> in mammary glands differ from one
another.<span style="mso-spacerun: yes">  </span>The presence of ER<span
style='font-family:Symbol'>a</span> in the mammary stroma cells is required for
the oestrogen proliferative response in the epithelium, which involves the
stroma-derived hepatocyte growth factor (<a
href="http://www.ebi.uniprot.org/entry/P14210"
title="UniProt entry for HGF_HUMAN">HGF</a>).<span style="mso-spacerun:
yes">  </span>Oestrogen-bound ER<span style='font-family:Symbol'>a</span> can
induce the progesterone receptor and mediate the differentiation of the
epithelium.<span style="mso-spacerun: yes">  </span>ER<span style='font-family:
Symbol'>b</span> cannot mediate oestrogen-dependent growth and development of
the mammary glands in the absence of ER<span style='font-family:Symbol'>a</span>.<span
style="mso-spacerun: yes">  </span>Integrin signalling is thought to interact
with HGF and oestrogen to modulate their proliferative effects.<span
style="mso-spacerun: yes">  </span>Oestrogen has been recognised as playing a
dominant role in the induction and progression of mammary carcinomas.<span
style="mso-spacerun: yes">  </span>The expression of the laminin-specific <a
href="http://www.ebi.uniprot.org/entry/P23229"
title="UniProt entry for ITA6_HUMAN">integrin <span style='font-family:Symbol'>a</span>-6</a>
is associated with breast cancer progression, laminin itself being able to
modulate the action of oestrogen in breast cancer cells.<span
style="mso-spacerun: yes">  </span>The over-expression of certain cofactors is
also associated with breast cancer.<span style="mso-spacerun: yes">  </span>The
drug tamoxifen, used in the treatment of breast cancer, acts as an ER
antagonist, and may act to inhibit growth factor production in stromal cells.</p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>Oestrogens
are essential for fertility, but are not required for the development of the
female reproductive tract.<span style="mso-spacerun: yes">  </span>ERs are
involved in ovulation, implantation, pregnancy maintenance and childbirth.<span
style="mso-spacerun: yes">  </span>It is thought that ER<span style='font-family:
Symbol'>a</span> may mediate the proliferative effects, while ER<span
style='font-family:Symbol'>b</span> mediates the differentiative effects of
oestrogen within the follicles.<span style="mso-spacerun: yes"> 
</span>Progesterone can act through the progesterone receptor (isoform A) to
negatively regulate the action of oestrogen by preventing ER<span
style='font-family:Symbol'>a</span> from activating transcription.<span
style="mso-spacerun: yes">   </span>Oestrogen and certain ER cofactors have
been implicated in the progression of ovarian cancers.</p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>In males,
oestrogen is required for normal testicular function, however exposure to it
during development can cause disorders in the structure and function of the
testis.<span style="mso-spacerun: yes">  </span>Oestrogens are produced by the
aromatisation of testosterone by the cytochrome P450 <a
href="http://www.ebi.uniprot.org/entry/P11511"
title="UniProt entry for CPV1_HUMAN">aromatase</a> enzyme complex in both
males and females.<span style="mso-spacerun: yes">  </span>ERs function to
regulate the expression of proteins involved in fluid reabsorption.<span
style="mso-spacerun: yes">  </span>ER<span style='font-family:Symbol'>b</span>
is widely expressed in the urogenital tract and the testis, whereas the level
of ER<span style='font-family:Symbol'>a</span> expression is low, and absent in
testis.<span style="mso-spacerun: yes">  </span>However, ER<span
style='font-family:Symbol'>a</span> is required for male fertility; disruption
of ER<span style='font-family:Symbol'>a</span> affects sperm morphology,
inhibits water reabsorption and decreases fertility.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1 align=left style='text-align:left'><i><span style='font-size:14.0pt;
mso-bidi-font-size:12.0pt;font-family:Arial'>Cardiovascular system<o:p></o:p></span></i></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>Oestrogens
affect the cardiovascular system, and have an influence on lipid profiles, fat
distribution, the tone of vascular and smooth muscle cells, endocrine factors
produced by the vascular wall (endothelins, nitric oxide), fibrinogen levels,
blood platelets, inflammatory factors and coagulation.<span
style="mso-spacerun: yes">  </span>Some of the effects of the ERs in the
cardiovascular system are known to be by non-transcriptional ER signal
transduction.<span style="mso-spacerun: yes">  </span>For instance, ER<span
style='font-family:Symbol'>a</span> can physically couple to PI3K
(phosphatidylinositol 3_OH kinase), leading to the activation of the PIK3
signalling cascade, and the subsequent phosphorylation and activation of nitric
oxide synthetases.<span style="mso-spacerun: yes">  </span>The release of
nitric oxide then triggers a vasodilatation effect on the vascular wall.</p>

<p class=MsoNormal style='text-indent:36.0pt'>The lack of oestrogen has been
linked to an increase in cardiovascular disease.<span style="mso-spacerun:
yes">  </span>Oestrogens may help modulate the cardiovascular effects of stroke
and epilepsy.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1 align=left style='text-align:left'><i><span style='font-size:14.0pt;
mso-bidi-font-size:12.0pt;font-family:Arial'>Immune system<o:p></o:p></span></i></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>ERs are
expressed in primary lymphoid organs and in peripheral immune cells.<span
style="mso-spacerun: yes">  </span>ER<span style='font-family:Symbol'>a</span>
is required for the development of the thymus in both sexes, while ER<span
style='font-family:Symbol'>b</span> may be responsible for the regulation of B
cell formation in bone marrow, supporting the action of oestrogen in immune
development and modulation.<span style="mso-spacerun: yes">  </span>Oestrogens
enhance the humoral immune response; oestrogen treatment was found to increase
the number of antibody-producing cells and the levels of autoantibodies without
increasing B cell count.<span style="mso-spacerun: yes">  </span>ERs regulate
the level of gonadotrophin-releasing hormone (GRH) and <a
href="http://www.ebi.uniprot.org/entry/Q8AWC1"
title="UniProt entry for Q8AWC1, GRHR">GRH receptor</a>, which are produced by
immune cells and have an enhancing effect on the immune response.</p>

<p class=MsoNormal style='text-indent:36.0pt'>Oestrogens are thought to play a
role in autoimmune disorders.<span style="mso-spacerun: yes">  </span>The
oestrogen/androgen balance is important in regulating the immune and
inflammatory responses in both males and females.<span style="mso-spacerun:
yes">  </span>Oestrogens enhance and testosterone suppresses the autoantibody
response, and a low androgen:oestrogen ratio has been found in patients of both
sexes with rheumatoid arthritis.<span style="mso-spacerun: yes">  </span>ERs
may have a role in systemic lupus erythematosus as well.<span
style="mso-spacerun: yes">  </span>Autoimmune disorders are more common in
women, possibly because of the higher levels of autoantibodies.<span
style="mso-spacerun: yes">  </span>Oestrogen appears to accelerate the progression
of autoimmune diseases by enhancing the T helper-2 pathway.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span><span
style="mso-spacerun: yes"> </span></p>

<h1 align=left style='text-align:left'><i><span style='font-size:14.0pt;
mso-bidi-font-size:12.0pt;font-family:Arial'>Central nervous system<o:p></o:p></span></i></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>Oestrogens
can exert effects on the brain, including cognitive function, co-ordination of
movement, pain and neuroprotection.<span style="mso-spacerun: yes"> 
</span>Oestrogens act as potent neurotrophic factors during development and in
adulthood; they influence sex-specific differentiation of the hypothalamus;
they act as potent growth factors that influence brain development, cell
survival, and neural plasticity; they function as neuroprotectants of the
nigrostriatal dopaminergic system.<span style="mso-spacerun: yes"> 
</span>Oestrogens can alter the expression of genes involved in apoptosis and
axonal regeneration.<span style="mso-spacerun: yes">  </span>The relative
levels of ER<span style='font-family:Symbol'>a</span> and ER<span
style='font-family:Symbol'>b</span> vary between different areas of the brain,
with the levels of ER<span style='font-family:Symbol'>a</span> being higher
than those of ER<span style='font-family:Symbol'>b</span> in the cortex,
hippocampus and hypothalamus.<span style="mso-spacerun: yes">  </span>ER<span
style='font-family:Symbol'>a</span> itself is expressed at a higher level in
the hypothalamus than in the hippocampus.<span style="mso-spacerun: yes"> 
</span>Oestrogen action in the brain is thought to occur through ER-dependent and
ER-independent mechanisms, which involve both the modulation of gene
transcription and non-genomic cytoplasmic signalling pathways.<span
style="mso-spacerun: yes">  </span>There are several examples of non-genomic
oestrogen action in the brain:<span style="mso-spacerun: yes"> 
</span>oestradiol-17<span style='font-family:Symbol'>b</span> can activate the
calcium and cAMP/PKA signalling pathways during the differentiation of midbrain
dopaminergic neurons; oestradiol-17<span style='font-family:Symbol'>b</span>
can protect hippocampal and cortical neurons from excitotoxic cell death
through the activation of the MAPK pathway. </p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>Recent
evidence shows oestrogens to be protective against Alzheimer’s disease,
Parkinson’s disease and schizophrenia, through their ability to protect against
neuronal cell death and by enhancing neurogenesis and cognitive function.<span
style="mso-spacerun: yes">  </span>Oestrogens may enhance recovery from
neurological injuries such as stroke; females usually suffer less stroke injury
than males.<span style="mso-spacerun: yes">  </span>The brain accelerates both
oestrogen synthesis and ER expression at sites of injury.<span
style="mso-spacerun: yes">  </span>Oestrogens are thought to exert their
neuroprotective effects through several different routes.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1 align=left style='text-align:left'><i><span style='font-size:14.0pt;
mso-bidi-font-size:12.0pt;font-family:Arial'>Skeletal system<o:p></o:p></span></i></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>Oestrogens
have an important role in bone metabolism and homeostasis, producing
significantly beneficial effects on skeletal growth and bone maturation.<span
style="mso-spacerun: yes">  </span>Oestrogens are involved in the modelling of bone
in adolescence, initiating pubertal bone growth and later limiting longitudinal
bone growth in women.<span style="mso-spacerun: yes">  </span>In adults,
oestrogens are crucial for the maintenance of bone mass in both males and
females, acting to suppress bone resorption by osteoclasts and to promote bone
formation by osteoblasts.<span style="mso-spacerun: yes">  </span>ER<span
style='font-family:Symbol'>a</span> mediates the growth-promoting effects of
oestrogen, while ER<span style='font-family:Symbol'>b</span> acts during
puberty to limit longitudinal and radial bone growth in females.<span
style="mso-spacerun: yes">  </span>Oestrogens regulate several factors
important for bone metabolism; these include the stimulation of the anabolic
growth factor <a href="http://www.ebi.uniprot.org/entry/P01343"
title="UniProt entry for  IGFA_HUMAN">IGF-1</a>; the inhibition of the
cytokines IL-1 (interleukin), tumour necrosis factor and <a
href="http://www.ebi.uniprot.org/entry/P05231"
title="UniProt entry for IL6_HUMAN">IL-6</a>, which are involved in bone
resorption; and the stimulation of osteoprotegrin, which is involved in the
inhibition of osteoclasts function.</p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>The
development of osteoporosis in women is associated with the decrease in
oestrogen levels following menopause.<span style="mso-spacerun: yes"> 
</span>Males with non-functional ERs, or who are unable to synthesize
oestrogen, are susceptible to osteoporosis.<span style="mso-spacerun: yes"> 
</span>The drug raloxifene used in the treatment of osteoporosis acts as an ER
agonist on bone and serum lipids, and as an antagonist on uterus and breast
tissue.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-weight:normal;font-style:normal'>Next:<span
style="mso-spacerun: yes">  </span><a href="Page_4.htm">What InterPro tells us</a><o:p></o:p></span></h2>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-weight:normal;font-style:normal'>Previous:<span
style="mso-spacerun: yes">  </span><a href="Page_2.htm">How the oestrogen
receptor works</a><o:p></o:p></span></h2>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span></p>

</div>

</body>

</html>
